Suppr超能文献

成人慢性免疫性血小板减少症脾切除的长期结果

Long-term results of splenectomy in adult chronic immune thrombocytopenia.

作者信息

Guan Yue, Wang Shixuan, Xue Feng, Liu Xiaofan, Zhang Lei, Li Huiyuan, Yang Renchi

机构信息

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

出版信息

Eur J Haematol. 2017 Mar;98(3):235-241. doi: 10.1111/ejh.12821. Epub 2016 Nov 7.

Abstract

OBJECTIVES

We performed this study in adult patients with chronic primary immune thrombocytopenia to explore the long-term efficacy and safety of splenectomy.

METHODS

Data of 174 patients who underwent splenectomy in our hospital from 1994 to 2014 were analyzed.

RESULTS

After splenectomy, 126 (72.4%) patients achieved a complete response (CR) and 28 (16.1%) achieved a response (R). Thirty-two (20.8%) responders relapsed with a median time of 24 months. Compared with non-responders and recurrent patients, the stable responders were younger and had higher preoperation and postoperation peak platelet count, later peak platelet count emergence time, and more megakaryocytes. Corticosteroid-dependent patients were more likely to response to splenectomy than those refractory to corticosteroid. We performed a relapse-free survival analysis among the 154 responders. In univariate analyses, corticosteroid dependent and time from diagnosis to splenectomy ≤24 months showed predictive value to persistent response. But only corticosteroid dependent was a significant predictor in multivariate analysis. The 30-d complication rate after the surgery was 25.9%. There were five (2.9%) patients experienced thrombosis and three (1.7%) refractory patients died during follow-up.

CONCLUSIONS

Splenectomy was a safe treatment with a cure rate of 58.0%. Corticosteroid dependent showed predictive value to persistent response.

摘要

目的

我们对成年慢性原发性免疫性血小板减少症患者进行了这项研究,以探讨脾切除术的长期疗效和安全性。

方法

分析了1994年至2014年在我院接受脾切除术的174例患者的数据。

结果

脾切除术后,126例(72.4%)患者达到完全缓解(CR),28例(16.1%)达到部分缓解(R)。32例(20.8%)缓解者复发,中位复发时间为24个月。与未缓解者和复发患者相比,持续缓解者年龄更小,术前和术后血小板峰值计数更高,血小板峰值计数出现时间更晚,巨核细胞更多。依赖皮质类固醇的患者比皮质类固醇难治性患者更可能对脾切除术有反应。我们对154例缓解者进行了无复发生存分析。单因素分析中,依赖皮质类固醇和从诊断到脾切除术的时间≤24个月对持续缓解有预测价值。但多因素分析中只有依赖皮质类固醇是显著的预测因素。术后30天并发症发生率为25.9%。随访期间有5例(2.9%)患者发生血栓形成,3例(1.7%)难治性患者死亡。

结论

脾切除术是一种安全的治疗方法,治愈率为58.0%。依赖皮质类固醇对持续缓解有预测价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验